Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
US7767803B2 · kind B2 · utility
57Cited by
28References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 7, 2006 |
| Grant date | Aug 3, 2010 |
| Priority date | — |
| Expiry date | Oct 7, 2028 |
Classification
- Technology area (CPC B)Performing Operations; Transporting
- CPC primaryB82Y5/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX™ method with 2′-O-methyl substituted nucleic acids, and cell surface SELEX™ are described herein. Also included are methods and compositions for the treatment and diagnosis of disease characterized by PSMA expression, using the described nucleic acid ligands.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.